1. Home
  2. BLTE

as 07-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Founded: 2018 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 1.3B IPO Year: 2022
Target Price: $50.25 AVG Volume (30 days): 67.8K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.19 EPS Growth: N/A
52 Week Low/High: $15.91 - $50.66 Next Earning Date: 08-06-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

BLTE Daily Stock ML Predictions

Share on Social Networks: